Evaluation of 5-[123I]-A-85380 and SPECT Imaging in Individuals With Parkinsons Disease
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
The underlying goal of this study is to assess [123I] 5-IA and SPECT imaging as a tool to
detect nicotinic receptor activity in the brain of PD patients. All study procedures will be
conducted at the Institute for Neurodegenerative Disorders (IND) and Molecular NeuroImaging
(MNI) in New Haven, CT. Approximately 10 patients with a diagnosis of PD without cognitive
changes will be recruited to participate in this study. Patients will be eligible to
participate if they have a diagnosis of PD of more than 2 years duration and have no
significant cognitive changes.